

### Communication

## **Total Synthesis of Thailanstatin A**

K. C. Nicolaou, Derek Rhoades, Manjunath Lamani, Manas R. Pattanayak, and S. Mothish Kumar J. Am. Chem. Soc., Just Accepted Manuscript • Publication Date (Web): 08 Jun 2016 Downloaded from http://pubs.acs.org on June 8, 2016

### **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Journal of the American Chemical Society is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

9 10

11 12

13 14 15

16 17

18

19

20

21

22

23

24

25 26 27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 58

59 60

## Total Synthesis of Thailanstatin A

K.C. Nicolaou,<sup>\*,†</sup> Derek Rhoades, Manjunath Lamani, Manas R. Pattanayak, S. Mothish Kumar

<sup>+</sup>Department of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005, United States

Supporting Information Placeholder

**ABSTRACT:** The total synthesis of the spliceosome inhibitor thailanstatin A has been achieved in a longest linear sequence of nine steps from readily available starting materials. A key feature of the developed synthetic strategy is the implementation of a unique, biomimetic asymmetric intramolecular oxa-Michael reaction/hydrogenation sequence that allows diastereodivergent access to highly functionalized tetrahydropyrans which can be used for the synthesis of designed analogues of this bioactive molecule.

Thailanstatin A (1, Figure 1A) is a newly discovered natural product with promising biological properties as a potential lead compound for drug discovery and development efforts. Isolated from *Thailandensis burkholderia* MSMB43, thailanstatin A (1) and its methyl ester (2, Figure 1A) exhibit low nanomolar to subnanomolar cytotoxicities against a number of human cancer cell lines.<sup>1,2</sup> Its mechanism of action, like its natural product congeners FR901464 (**3**, Figure 1A) and spliceostatin A (**4**, Figure 1A),<sup>3</sup> has been shown to involve inhibition of the spliceosome,<sup>4</sup> the cellular machinery responsible for editing mRNA as it emerges from the transcription of DNA through site specific removal of introns and religation of the remaining exon sequences prior to translation.<sup>5</sup> Given that the spliceosome of cancer cells is more active and displays higher mutation rates than those of normal cells, this cellular component became a validated target for inhibition as a new paradigm for discovery and development of novel anticancer drugs.<sup>6</sup>

The improved stability of **1** vs. **3** and **4** (the latter suffering from lactol and glycoside labilities) and its carboxylic acid functionality constitute attractive features for **1** and its analogues as payloads for appropriate drug delivery systems, such as antibody drug conjugates (ADCs).<sup>7</sup> Indeed, since its isolation, significant advances have been made to produce **1** in larger quantities *via* optimized fermentation strategies.<sup>8</sup> A chemical synthesis of **1** has the potential to render this molecule readily available and, more importantly, provide a general and expedient entry into a plethora of analogues for biological investigations. In this communication, we describe a short and efficient total synthesis of thailanstatin A (**1**).

Figure 1B depicts, in retrosynthetic format, the synthetic strategy developed toward thailanstatin A (1). Thus, disconnection of 1 through a Suzuki coupling led to advanced intermediates vinyl boronate **5** and vinyl iodide **6**. Further disconnection of **5** at the



Figure 1. A: Molecular structures of thailanstatin A (1), its methyl ester (2), and related natural products FR901464 (3) and spliceostatin A (4). B: Retrosynthetic analysis of 1 through intermediates 5 and 6.

amide linkage (amide bond formation), the vinyl boronate olefinic bond (cross metathesis), and the tetrahydropyran system (oxa-Michael reaction) as indicated in Figure 1B revealed doubly conjugated hydroxy aldehyde 7 and acetoxy carboxylic acid 8 as potential key building blocks. Disassembly of 6 at the vinyl iodide (Takai olefination), epoxide (directed epoxidation) and tetrahydropyran (Mukaiyama–Michael reaction) sites traced this advanced intermediate back to the known and readily available pyranone 9 as a starting material.

For the synthesis of the 2,3,5,6-tetrasubstituted tetrahydropyran ring embedded within intermediate **5**, we were inspired by the proposed biosynthesis of **1** (Figure 2A), which involves an intramolecular oxa-Michael reaction of an acyl carrier protein (ACP)bound  $\alpha,\beta$ -unsaturated thioester of a polyketide synthase (PKS) complex.<sup>1,9</sup> However, in an effort to preserve atom and step economy,<sup>10</sup> and in order to establish a foundation for a diastereodivergent approach to highly functionalized tetrahydropyrans, we sought to explore the asymmetric intramolecular oxa-Michael (AIOM) reac-



**Figure 2.** A: Proposed biosynthetic formation of the tetrasubstituted tetrahydropyran system of thailanstatin A (1) through an oxa-Michael reaction. B: Proposed diastereodivergent approach to tetrasubstituted dihydropyrans **II** from  $\alpha, \beta, \gamma, \delta$ -unsaturated aldehyde **I** through asymmetric intramolecular oxa-Michael (AIOM) reaction and tetrasubstituted tetrahydropyrans **III** from **II** *via* hydrogenation.

The synthesis of vinyl boronate 5 from Garner aldehyde  $17^{12}$  is summarized in Scheme 1. Thus, a-methyliodomethylenation of 17 under Stork-Zhao conditions<sup>13</sup> furnished olefinic iodo-Boc derivative **18** (54% yield, Z:E ca. 95:5, chromatographically separated) from which the desired iodo-Phth derivative 19 was generated by protecting group exchange (formic acid; then phthalic anhydride, Et<sub>3</sub>N, DMAP cat.) in 80% overall yield. Stille coupling of the latter with hydroxy stannane  $20^{14}$  [Pd<sub>2</sub>(dba)<sub>3</sub>, 73% yield] led to diene 22, whose MnO<sub>2</sub> oxidation afforded the desired  $(E_1Z)$ - $a_1\beta_1\gamma_1\delta_2$ unsaturated aldehyde 7 in 90% yield. The same aldehyde (7) could also be obtained in one step directly from vinyl iodide 19 and aldehyde stannane **21**<sup>15</sup> through Stille coupling [Pd<sub>2</sub>(dba)<sub>3</sub>, 60% yield]. Exposure of 7 to diaryl prolinol catalyst 23<sup>16</sup> (0.2 equiv) in the presence of benzoic acid (0.2 equiv) in CH<sub>2</sub>Cl<sub>2</sub> induced the desired asymmetric intramolecular oxa-Michael reaction, providing 2,6-syn dihydropyran 24 in 77% yield (dr > 20:1). Aldehyde 24 proved to be a challenging substrate for the subsequent hydrogenation reaction. Optimal results were achieved by masking the aldehyde moiety as a diethoxy acetal [25, CH(OEt)<sub>3</sub>, CSA, 91% yield]. It was found that stereoselective hydrogenation from the *a*-face of the ring system could be achieved with 10% Pd/C in ethanol under a H<sub>2</sub> atmosphere at high pressure (80 bar) to afford 2,3,5,6-syn tetrahydropyran 26 (54% yield) after mild aqueous acidic workup. Interestingly, however, and after extensive experimentation, it was discovered that aldehyde 24 could be efficiently hydrogenated directly (H<sub>2</sub>, 80 bar) in excellent yield with 10% Pd/C in hexafluoroisopropanol (HFIP) solvent, albeit with modest diastereoselectivity (93%, 7:3 dr, 65% yield for 26). Methylenation (Tebbe reagent) of saturated aldehyde 26 provided olefin 27 in 76% yield. Rupture of the phthalimide moiety within the latter with methylhydrazine, followed by direct amide coupling with carboxylic acid 817 (EDCI, NMM) led to amide 28 (73% yield), an advanced intermediate reported in the synthesis of FR901464.3d Cross metathesis of 28 with commercially available isopropenylboronic acid pinacol ester 29 (Grubbs II cat., ClCH<sub>2</sub>CH<sub>2</sub>Cl) afforded vinyl boronate 5 in 71% yield.

#### Scheme 1. Synthesis of Vinyl Boronate 5<sup>a</sup>



<sup>a</sup>Reagents and conditions: (a) PPh<sub>3</sub>EtI (2.0 equiv), *n*-BuLi (2.0 equiv), THF, 25 °C, 15 min; then  $I_2$  (1.9 equiv); then NaHMDS (1.9 equiv); then 17 (1.0 equiv), THF,  $-78 \rightarrow -20 \rightarrow -78$  °C, 1.5 h, 54% (Z:E ca. 95:5); (b) formic acid (neat), 25 °C, 10 min; then phthalic anhydride (1.1 equiv), Et<sub>3</sub>N (20 equiv), DMAP (0.1 equiv), CHCl<sub>3</sub>, 70 °C, 48 h, 80% overall; (c) 20 (1.2 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.1 equiv), NMP, 25 °C, 16 h, 73%; (c) **21** (2.0 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.1 equiv), NMP, 25 °C, 16 h, 60%; (d) MnO<sub>2</sub> (20 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 1 h, 90%; (e) 23 (0.2 equiv), PhCO<sub>2</sub>H (0.2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 6.5 h, 77%; (f) 10% Pd/C  $(50\% \ w/w)$ , H<sub>2</sub> (80 bar), HFIP, 25 °C, 24 h, 93% (dr 7:3); (g) CH(OEt)<sub>3</sub> (10 equiv), CSA (0.1 equiv), EtOH, 25 °C, 2 h, 91%; (h) 10% Pd/C (35% w/w), H<sub>2</sub> (80 bar), EtOH, 25 °C, 15 h; then 0.1 M aq. HCl (3.0 equiv), acetone, 25 °C, 10 min, 54% overall; (i) Tebbe reagent (1.0 equiv), THF,  $-20 \rightarrow 0$  °C, 1 h, 76%; (j) MeNHNH<sub>2</sub> (10 equiv), PhH, 25 °C, 2 h; then EDCI (3.0 equiv), NMM (3.0 equiv), 8 (2.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 30 min, 73% overall; (k) **29** (5.0 equiv), Grubbs II cat. (0.1 equiv), ClCH<sub>2</sub>CH<sub>2</sub>Cl, 80 °C, 1 h, 71%. Abbreviations: Boc = tert-butyloxycarbonyl; CSA = camphorsulfonic acid; dba = dibenzylideneacetone; DMAP = N,N-dimethylaminopyridine; EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HFIP = hexafluoroisopropanol; HMDS = hexamethyldisilazide; NMM = N-methylmorpholine; NMP = N-methyl-2-pyrrolidinone; Phth = phthaloyl; pin = pinacolato; TMS = trimethylsilyl.

During our exploration of the oxa-Michael reaction of aldehyde **7**, it was discovered that the reaction displays an unusually high degree of catalyst control, especially as compared with typical AIOM reactions, in which *a*, $\beta$ -unsaturated aldehydes, esters, and amides generally favor the 2,6-*syn* tetrahydropyran product.<sup>11</sup> Elegant studies by Hong have also shown that olefin geometry (*i.e. E* or *Z a*, $\beta$ -unsaturated aldehydes) can render AIOM reactions stere-oselective as a consequence of substrate control, while catalyst control alone is rarely useful for high levels of 2,6-*anti* stereoselectivity.<sup>18</sup> As depicted in Scheme 2A, we found that 2,6-*syn* dihydropyran **24** or 2,6-*anti* dihydropyran 11-*epi*-**24** (half-chair structures confirmed by <sup>1</sup>H NOE spectroscopy, see Supporting Information for details) could be accessed in comparable yields with virtually

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 58

59 60



<sup>a</sup>Reagents and conditions: (a) **23** or *ent*-**23** (0.2 equiv), PhCO<sub>2</sub>H (0.2 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 6.5 h, 77% for **24** (dr > 20:1), 64% for 11-*epi*-**24** (dr > 20:1); (b) [Ir(Py)(PCy<sub>3</sub>)(COD)BARF] (0.05 equiv), H<sub>2</sub> (1 atm), CH<sub>2</sub>Cl<sub>2</sub>, 25 °C, 10 h; then 0.1 M aq. HCl (3.0 equiv), acetone, 25 °C, 10 min, 85% overall; (c) 10% Pd/C (35% w/w), H<sub>2</sub> (80 bar), EtOH, 25 °C, 24 h; then 0.1 M aq. HCl (3.0 equiv), acetone, 25 °C, 10 min, 54% overall. Abbreviations: BARF = tetrakis[3,5-bis(trifluoromethyl)phenyl] borate; COD = 1,5-cyclooctadiene; Cy = cyclohexyl; Py = pyridine.

complete stereoselectivity, based solely on catalyst control. In addition, complementary stereoselectivity for the hydrogenation of acetal substrate 25 could be achieved under specific reaction conditions. Thus, as shown in Scheme 2B, treatment of 25 with [Ir(Py)(PCy<sub>3</sub>)(COD)BARF] catalyst,<sup>19</sup> a counteranion analogue of Crabtree's catalyst, in CH2Cl2 under 1 atm of H2 cleanly provided 12-epi-26 after workup with dilute acid. Delivery of hydrogen to the  $\beta$ -face of **25** was likely facilitated by the O atom(s) of the acetal and/or the imide carbonyl O atom(s). In contrast, use of heterogeneous conditions led to 26, the product of H<sub>2</sub> delivery from the *a*face of **25**, as dictated by the hindered nature of its  $\beta$ -face. The relative configurations of 26 and 12-epi-26 were confirmed by <sup>1</sup>H NOE studies, which also revealed a chair conformation for 12-epi-26 and a boat conformation for 26 (due to the large 1,3 diaxial interaction between the bulky N-phthaloyl moiety and the adjacent axial methyl group, see SI for details). This AIOM/hydrogenation approach may prove useful as a general method for the synthesis of highly substituted tetrahydropyrans.

The syntheses of key vinyl iodide building blocks **6** and **6a** are summarized in Scheme 3A. Thus, pyranone derivative  $9^{20}$  was reacted with ketene silyl acetal **10** in the presence of iodine to afford stereoselectively, after treatment with methanolic K<sub>2</sub>CO<sub>3</sub>, ketone methyl ester **11** in 98% yield on a 10 gram scale.<sup>21</sup> Wittig reaction of the latter with the ylide derived from the phosphonium salt of MeBr and *t*-BuOK yielded terminal olefin **12** (80% yield), whose conversion to aldehyde **14** was achieved by selective monodesilylation (PPTS, 98% yield) followed by Swern oxidation [(COCl)<sub>2</sub>, DMSO; Et<sub>3</sub>N, 96% yield] of the resulting primary alcohol (*i.e.* **13**).<sup>12</sup> Takai olefination (CrCl<sub>2</sub>, CHI<sub>3</sub>)<sup>22</sup> of aldehyde **14** then led to the desired *E*-iodo-olefin **15** in 58% yield. Desilylation of the latter (TBAF, 93% yield) furnished allylic alcohol **16**. Saponification of **16** (LiOH) provided acid **16a** as a crystalline solid (m.p. = 128–136) °C, EtOAc). X-Ray crystallographic analysis (see ORTEP in Scheme 3B and SI for details) unambiguously confirmed the 2,6anti configuration of the tetrahydropyran ring system. Directed epoxidation of **16** with *t*-BuOOH and VO(acac)<sub>2</sub> cat. delivered the targeted hydroxy epoxide methyl ester **6a** (74% yield), whose <sup>1</sup>H NOE analysis confirmed its relative stereochemistry (Scheme 3B, see SI for details).<sup>23</sup> Subsequent conversion of methyl ester **6a** to carboxylic acid **6** was accomplished through the action of LiOH (90% yield).

#### Scheme 3. Synthesis of Vinyl Iodides 6 and 6a\*



<sup>a</sup>Reagents and conditions: (a) **10** (2.0 equiv), I<sub>2</sub> (0.1 equiv), MeCN, – 30  $\rightarrow$  -20 °C, 30 min; then K<sub>2</sub>CO<sub>3</sub> (0.1 equiv), MeOH, 25 °C, 10 min, 98% overall; (b) Ph<sub>3</sub>PCH<sub>3</sub>Br (2.5 equiv), *t*-BuOK (2.0 equiv), THF, 0 °C, 1 h, 72%; (c) PPTS (1.0 equiv), MeOH, 25 °C, 12 h, 98%; (d) (COCl)<sub>2</sub> (1.5 equiv), DMSO (3.0 equiv), then Et<sub>3</sub>N (5.0 equiv), CH<sub>2</sub>Cl<sub>2</sub>, -78  $\rightarrow$  -55 °C, 3 h, 96%; (e) CrCl<sub>2</sub> (6.0 equiv), CHI<sub>3</sub> (3.0 equiv), THF, 25 °C, 12 h, 58%; (f) TBAF (2.0 equiv), THF, 0  $\rightarrow$  25 °C, 30 min, 93%; (g) LiOH (8.0 equiv), 1:1 THF/H<sub>2</sub>O, 25 °C, 12 h, 98%; (h) VO(acac)<sub>2</sub> (0.1 equiv), *t*-BuOOH (2.1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, 0  $\rightarrow$ 25 °C, 10 h, 74%; (i) LiOH (1.5 equiv), 10:1 THF/H<sub>2</sub>O, 0  $\rightarrow$  25 °C, 12 h, 90%. Abbrevations: DMSO = dimethyl sulfoxide; PPTS = pyridinium *p*-toluenesulfonate; TBAF = *n*-tetrabutylammonium fluoride; TBS = *tert*-butyldimethylsilyl.

Scheme 4 depicts the final coupling of vinyl iodides **6** and **6a** with vinyl boronate **5** to afford the desired targets **1** and **2**, respectively. At first, methyl ester **2** was obtained through Suzuki coupling utilizing Pd(PPh<sub>3</sub>)<sub>4</sub> cat. and Tl(OEt) as the base.<sup>24</sup> While the reaction was completed quickly (< 15 min, 25 °C), the basic thallium(I) salts caused significant decomposition, presumably due to epoxide and acetate ruptures. To circumvent this problem, the more stable Pd(dppf)Cl<sub>2</sub>•CH<sub>2</sub>Cl<sub>2</sub> complex was used with K<sub>3</sub>PO<sub>4</sub> as the base in a biphasic system to deliver thailanstatin A (**1**) and its methyl ester **2** (64% yield), respectively. Despite our efforts to purify **1** by standard chromatographic techniques, we were relegated to employing semipreparative HPLC for its purification (see SI for details). The yield was approximated by treatment of crude **1** with TMSCHN<sub>2</sub> to generate chromatographically stable methyl ester **2** (52% overall yield).

The high convergency of the developed synthetic strategy amounts to a rapid and efficient synthesis of thailanstatin A(1) and

# Scheme 4. Completion of the Total Synthesis of Thailanstatin A (1) and its Methyl Ester (2)<sup>a</sup>



**2**: thailanstatin A methyl ester (R = Me)  $\leftarrow$  b) TMSCHN<sub>2</sub>

<sup>a</sup>Reagents and conditions: (a)  $Pd(dppf)Cl_2 \cdot CH_2Cl_2$  (0.02 equiv), K<sub>3</sub>PO<sub>4</sub> (1.0 equiv), **5** (1.1 equiv), **6** or **6a** (1.0 equiv), 1,4dioxane/MeCN/H<sub>2</sub>O (3:1:1), 25 °C, 10 min, 52% for **1**, 64% for **2**; (b) TMSCHN<sub>2</sub> (3.0 equiv), 3:2 PhMe/MeOH,  $0 \rightarrow 25$  °C, 3 h, quant. Abbreviations: dppf = diphenylphosphinoferrocenyl.

its congeners, while the stereochemical divergency of the method to produce tetrasubstituted tetrahydropyrans bodes well for its application to the construction of a variety of designed analogues within this family of bioactive molecules for biological evaluation. Such studies may lead to the identification of useful biological tools and potential drug candidates to be developed as anticancer drugs or employed as payloads for ADCs or other cancer cell selective delivery systems for the purposes of targeted and personalized cancer therapies.

#### ASSOCIATED CONTENT

#### Supporting Information

Experimental procedures and characterization data for all compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

#### AUTHOR INFORMATION

#### Corresponding Author

\*<u>kcn@rice.edu</u>.

#### Notes

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59 60 The authors declare no competing financial interests.

#### ACKNOWLEDGMENT

D.R. is a University of California, San Diego graduate student; all work was carried out at Rice University. We thank Drs. Lawrence B. Alemany and Quinn Kleerekoper (Rice University) for NMRspectroscopic assistance, Drs. Christopher L. Pennington (Rice University) and Ian Riddington (University of Texas at Austin) for massspectrometric assistance, and Dr. James D. Korp (University of Houston) for X-ray crystallographic assistance. We also thank Yi-Chiang "Eric" Cheng (University of North Texas Health Science Center) for a sample of natural thailanstatin A for comparison purposes. This work was supported by The Cancer Prevention & Research Institute of Texas (CPRIT) and The Welch Foundation (grant C-1819).

#### REFERENCES

Liu, X.; Biswas, S.; Berg, M. G.; Antapli, C. M.; Xie, F.; Wang,
 Q.; Tang, M.-C.; Tang, G.-L.; Zhang, L.; Dreyfuss, G.; Cheng, Y.-Q. J. Nat.
 Prod. 2013, 76, 685.

(2) He, H.; Ratnayake, A. S.; Janso, J. E.; He, M.; Yang, H. Y.; Loganzo, F.; Shor, B.; O'Donnell, C. J.; Koehn, F.E. *J. Nat. Prod.* **2014**, *77*, 1864.

(3) For syntheses of 4 and 5, see: (a) Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. *J. Am. Chem. Soc.* 2000, *122*, 10482. (b) Thompson, C. F.; Jamison, T. F.; Jacobsen, E. N. *J. Am. Chem. Soc.* 2001, *123*, 9974. (c) Horigome, M.; Motoyoshi, H.; Watanabe, H.; Kitahara, T. *Tetrahedron Lett.* 2001, *42*, 8207. (d) Albert, B. J.; Sivaramakrishnan, A.; Naka, T.; Koide, K. *J. Am. Chem. Soc.* 2006, *128*, 2792. (e) Motoyoshi, H.; Horigome, M.; Watanabe, H.; Kitahara, T. *Tetrahedron* 2006, *62*, 1378. (f) Albert, B. J.; Sivaramakrishnan, A.; Naka, T.; Caicki, N. L.; Koide, K. *J. Am. Chem. Soc.* 2007, *129*, 2648. (g) Ghosh, A. K.; Chen, Z.-H. *Org. Lett.* 2013, *15*, 5088. (h) Ghosh, A. K.; Chen, Z.-H.; Effenberger, K. A.; Jurica, M.S. J. Org. Chem. 2014, *79*, 5697–5709.

(4) (a) Kaida, D.; Motoyoshi, H.; Tashiro, E.; Nojima, T.; Hagiwara, M.; Ishigami, K.; Watanabe, H.; Kitahara, T.; Yoshida, T.; Nakajima, H.; Tani, T.; Horinouchi, S.; Yoshida, M. *Nat. Chem. Biol.* **2007**, *3*, 576. (b) Corrionero, A.; Miñana, B.; Valcárcel, J. *Genes Dev.* **2011**, *25*, 445.

(5) (a) Das, B. K.; Xia, L.; Palandjian, L.; Gozani, O.; Chyung, Y.;
Reed, R. *Mol. Cell. Biol.* **1999**, *19*, 6796–6802. (b) Zhou, Z. L.; Licklider,
L. J.; Gygi, S. P.; Reed, R. *Nature* **2002**, *419*, 182–185. (c) Wan, R.; Yan, C.;
Bai, R.; Wang, L.; Huang, M.; Wong, C. C. L.; Shi, Y. *Science* **2016**, *351*, 466. (d) Agafonov, D. A.; Kastner, B.; Dybkov, O.; Hofele, R. V.; Liu, W.
T.; Urlaub, H.; Lührmann, R.; Stark, H. *Science* **2016**, *351*, 1416.

(6) (a) Bonnal, S.; Vigevani, L.; Valcárcel, J. *Nat. Rev. Drug Disc.* **2012**, *11*, 847. (b) Hsu, T.Y.-T.; Simon, L.M.; Neill, N.J.; Marcotte, R.; Sayad, A.; Bland, C.S.; Echeverria, G.V.; Sun, T.; Kurley, S.J.; Tyagi, S.; Karlin, K.L.; Dominguez-Vidaña, R.; Hartman, J.D.; Renwick, A.; Scorsone, K.; Bernardi, R.J.; Skinner, S.O.; Jain, A.; Orellana, M.; Lagisetti, C.; Golding, I.; Jung, S.Y.; Neilson, J.R.; Zhang, X.H.-F.; Cooper, T.A.; Webb, T.R.; Neel, B.G.; Shaw, C.A.; Westbrook, T.F. *Nature* **2015**, *525*, 384.

(7) Chari, R. V. J.; Miller, M. L.; Widdison, W.C. Angew. Chem., Int. Ed. 2014, 53, 3796.

(8) (a) Dirico, K. J.; Eustáquio, A. S.; Green, M. E.; He, H.; He, M.; Koehn, F. E.; O'Donnell, C. J.; Puthenveetil, S.; Ratnayake, A. S.; Subramanyam, C.; Teske, J. A.; Yang, H. Y. International Patent WO 068443 A1: 2014. (b) Eustáquio, A. S.; Chang, L.-P.; Steele, G. L.; O'Donnell, C. J.; Koehn, F.E. *Metab. Eng.* **2016**, *33*, 67.

- (9) Helfrich, E. J. N.; Piel, J. Nat. Prod. Rep. 2016, 33, 231.
- (10) Trost, B. M. Angew. Chem., Int. Ed. 1995, 34, 259.
- (11) (a) Nising, C. F.; Bräse, S. Chem. Soc. Rev. 2008, 37, 1218. (b)
- Nising, C. F.; Bräse, S. Chem. Soc. Rev. 2012, 41, 988
  - (12) Dondoni, A.; Perrone, D. Org. Synth. 2004, 77, 320.
  - (13) (a) Stork, G.; Zhao, K. *Tetrahedron Lett.* **1989**, *30*, 2173. (b)
- Chen, J.; Wang, T.; Zhao, K. *Tetrahedron Lett.* **1994**, *35*, 2827.

(14) For a new and convenient preparation of this building block, see SI. For a previous preparation, see: Pilli, R. A.; de Andrade, C. K. Z.; Souto, C. R. O.; de Meijere, A. *J. Org. Chem.* **1998**, *63*, 7811.

- (15) Johnson, C. R.; Kadow, J. F. J. Org. Chem. 1987, 52, 1493.
- (16) (a) Franzén, J.; Marigo, M.; Fielenbach, D.; Wabnitz, T.C.;

Kjærsgaard, A.; Jørgensen, K.A. *J. Am. Chem. Soc.* **2005**, *127*, 18296. (b) Hayashi, Y.; Gotoh, H.; Hayashi, T.; Shoji, M. *Angew. Chem. Int. Ed.* **2005**, *44*, 4412.

(17) For a new and convenient preparation of this building block, see SI. For a previous preparation, see Ref. 3a.

(18) Lee, K.; Kim, H.; Hong, J. Org. Lett. 2011, 13, 2722.

(19) Lightfoot, A.; Schnider, P.; Pfaltz, A. *Angew. Chem., Int. Ed.* **1998**, *37*, 2897.

- (20) Fujiwara, T.; Hayashi, M. J. Org. Chem. 2008, 73, 9161.
- (21) Deuri, S.; Phukan, P. J. Phys. Org. Chem. 2012, 25, 1228.
- (22) Takai, K.; Nitta, K.; Utimoto, K. *J. Am. Chem. Soc.* **1986**, *108*, 7408.
- (23) Itoh, T.; Jitsukawa, K.; Kaneda, K.; Teranishi, S. *J. Am. Chem. Soc.* **1979**, *101*, 159.

(24) Frank, S. A.; Chen, H.; Kunz, R. K.; Schnaderbeck, M. J.; Roush, W. R. *Org. Lett.* **2000**, *2*, 2691.

# Total Synthesis of Thailanstatin A

K.C. Nicolaou,\*<sup>,†</sup> Derek Rhoades, Manjunath Lamani, Manas R. Pattanayak, S. Mothish Kumar





TOC Drawing 44x23mm (300 x 300 DPI)